Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Health effects of Chernobyl nuclear crisis remain unknown 25 years after incident

Though it has been 25 years since a disastrous explosion at the Chernobyl nuclear power plant in Ukraine sent radioactive material into the air, affecting Russia, Ukraine and Belarus, as well as the rest of the world, "experts are still debating the long-term health effects of the disaster," the Los Angeles Times' "Booster Shots" blog reports.

28 Apr 2011

Northstar Healthcare acquires ownership interests in Texas based radiation therapy cancer treatment centers

Northstar Healthcare Inc. today announced that it entered into an agreement to acquire certain ownership interests in four physician owned radiation therapy cancer treatment centers from Dr. Chris Phan, a radiation oncologist. Dr. Phan is founder and Chief Executive Officer of Expert Oncology Network Solutions, LLC (EONS). EONS has been instrumental in developing and consulting with cancer centers across Texas.

28 Apr 2011

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

AstraZeneca announced today the launch of "click-to-chat" on CRESTOR.com and PurplePill.com. The new "click-to-chat" technology gives consumers an option to contact a live AstraZeneca customer service representative with just a click of a button.

28 Apr 2011

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.

28 Apr 2011

GPs could offer simple test for early detection of ovarian cancer

Health experts have said that hundreds of lives could be saved a year if GPs were quicker to spot symptoms of the disease - dubbed a “silent killer” because it is hard to diagnose early enough. Ovarian cancer kills almost 4,400 women in Britain every year. It kills one every two hours that makes it the fourth most common cancer in females. While almost three times as many die from breast cancer, those diagnosed with ovarian cancer are far more likely to die earlier.

28 Apr 2011

ASTRO develops new thoracic radiotherapy guideline

The American Society for Radiation Oncology has developed a guideline for the use of external beam radiation therapy, endobronchial brachytherapy and concurrent chemotherapy to palliate thoracic symptoms caused by advanced lung cancer. The guideline will be published in Practical Radiation Oncology, an official journal of ASTRO.

28 Apr 2011

Northwestern Asthma-COPD Program with palliative medicine can enhance patient care

When faced with a long-term illness, patients often retreat or are left feeling hopeless, a response that can negatively impact one's prognosis and impair their quality of life. When coping measures are offered however, the opposite can hold true.

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Cancer researchers at hundreds of sites nationwide are about to launch a SWOG-led clinical trial that could keep thousands of breast cancer patients from getting chemotherapy that is unlikely to do them any good.

27 Apr 2011

Researchers investigate new device that can recognize early heart attack signs

When a heart attack begins, a stopwatch starts. With each passing minute heart tissue is deprived of blood, causing it to deteriorate or die. In order to minimize damage to the heart, blood flow must be restored promptly, or the effects can be serious, often even fatal.

27 Apr 2011

Brain-derived protein in colorectal cancer

Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored.

27 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

In a new study published online in the journal Cancer, it was said that when faced with life-threatening cancer, minority patients like blacks may be more likely to drain their bank accounts to extend life than whites.

26 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Accuray announces expiration of HSR waiting period for TomoTherapy acquisition

Accuray Incorporated, a global leader in the field of radiosurgery, today announced the expiration of the mandatory, pre-merger waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, in connection with the previously announced acquisition of TomoTherapy Incorporated.

26 Apr 2011

Ohio State Roundtable to discuss about cancer drug development

The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Friends of Cancer Research are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

26 Apr 2011

Pharmacyclics receives Servier's $7 million milestone payment for HDAC inhibitor

Pharmacyclics, Inc. announced today that it has received a $7 million milestone payment for its histone deacetylase inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier based on an ex-US collaboration agreement signed in April of 2009.

26 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Oncology News and Research

Further Reading

Health effects of Chernobyl nuclear crisis remain unknown 25 years after incident

Northstar Healthcare acquires ownership interests in Texas based radiation therapy cancer treatment centers

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

GPs could offer simple test for early detection of ovarian cancer

ASTRO develops new thoracic radiotherapy guideline

Northwestern Asthma-COPD Program with palliative medicine can enhance patient care

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Researchers investigate new device that can recognize early heart attack signs

Brain-derived protein in colorectal cancer

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

Millennium submits two VELCADE sNDAs to FDA

Accuray announces expiration of HSR waiting period for TomoTherapy acquisition

Ohio State Roundtable to discuss about cancer drug development

Pharmacyclics receives Servier's $7 million milestone payment for HDAC inhibitor

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

Event guide: 10th CAR-TCR Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News